A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes

EMBO Molecular Medicine

Volumn 7, Issue 4, 2015, Pages 450-463

  Khandelwal, Nisit ^a   Breinig, Marco ^a,b   Speck, Tobias ^a   Michels, Tillmann ^a   Kreutzer, Christiane ^a   Sorrentino, Antonio ^a   Sharma, Ashwini Kumar ^a   Umansky, Ludmila ^a   Conrad, Heinke ^a   Poschke, Isabel ^b   Offringa, Rienk ^b   König, Rainer ^a,c,d   Bernhard, Helga ^e   Machlenkin, Arthur ^f   Boutros, Michael ^a,b   Beckhove, Philipp ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d HANS KNÖLL INSTITUTE   (Germany)

^e KLINIKUM DARMSTADT   (Germany)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cancer immunotherapy; Immune suppression; RNAi screen

Indexed keywords

BETA ACTIN; CHEMOKINE RECEPTOR CCR9; SURVIVIN; CC CHEMOKINE RECEPTOR 9; CD274 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTRACELLULAR SIGNALING; MELANOMA CELL; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; ANIMAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MCF 7 CELL LINE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TH1 CELL;

ANIMALS; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MCF-7 CELLS; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CCR; RNA INTERFERENCE; TH1 CELLS;

EID: 84926147405     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404414     Document Type: Article

References (50)

1. Abouzahr S, Bismuth G, Gaudin C, Caroll O, Van Endert P, Jalil A, Dausset J, Vergnon I, Richon C, Kauffmann A et al (2006) Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 103: 1428-1433
2. Bachmann MF, Barner M, Viola A, Kopf M (1999) Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol 29: 291-299
3. Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J (2012) Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Investig 122: 2369-2383
4. Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, Dipaolo RJ, Teague RM (2013) Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance. Cancer Res 73: 605-616
5. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64: 1140-1145
6. Boutros M, Bras LP, Huber W (2006) Analysis of cell-based RNAi screens. Genome Biol 7: R66
7. Brackertz B, Conrad H, Daniel J, Kast B, Kronig H, Busch DH, Adamski J, Peschel C, Bernhard H (2011) FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. Blood Cancer J 1: e11
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 366: 2455-2465
9. Brown CE, Wright CL, Naranjo A, Vishwanath RP, Chang WC, Olivares S, Wagner JR, Bruins L, Raubitschek A, Cooper LJ et al (2005) Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297: 39-52
10. Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 14: 181-196
11. Caron L, Abraham N, Pawson T, Veillette A (1992) Structural requirements for enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Mol Cell Biol 12: 2720-2729
12. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19: 565-594
13. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW (2004) Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases. Cancer Res 64: 406-414
14. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800
15. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342
16. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE et al (2010) CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16: 6122-6131
17. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355-366
18. Fallarino F, Gajewski TF (1999) Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163: 4109-4113
19. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P (2013) Advances in the development of cancer immunotherapies. Trends Immunol 34: 90-98
20. Gilbert DF, Erdmann G, Zhang X, Fritzsche A, Demir K, Jaedicke A, Muehlenberg K, Wanker EE, Boutros M (2011) A novel multiplex cell viability assay for high-throughput RNAi screening. PLoS ONE 6: e28338
21. Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC (2008) CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. Nat Immunol 9: 1253-1260
22. Hill HR, Martins TB (2006) The flow cytometric analysis of cytokines using multi-analyte fluorescence microarray technology. Methods 38: 312-316
23. Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW Jr (2011) CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol 38: 1279-1285
24. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC et al (2000) Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 192: 761-768
25. Li S, Chen S, Xu X, Sundstedt A, Paulsson KM, Anderson P, Karlsson S, Sjogren HO, Wang P (2000) Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 191: 985-994
26. Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M (2008) Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs. Cancer Res 68: 2006-2013
27. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH et al (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138: 1429-1440
28. Muller P, Kuttenkeuler D, Gesellchen V, Zeidler MP, Boutros M (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436: 871-875
29. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68: 7228-7236
30. Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32: 79-90
31. Qi Z, Sun XH (2004) Hyperresponse to T-cell receptor signaling and apoptosis of Id1 transgenic thymocytes. Mol Cell Biol 24: 7313-7323
32. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296
33. Shen X, Mailey B, Ellenhorn JD, Chu PG, Lowy AM, Kim J (2009) CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg 13:1955-1962; discussion 1962.
34. Singh R, Stockard CR, Grizzle WE, Lillard JW Jr, Singh S (2011) Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol 39: 373-381
35. Slifka MK, Rodriguez F, Whitton JL (1999) Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature 401: 76-79
36. Strauss G, Guckel B, Wallwiener D, Moldenhauer G (1999) Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Clin Cancer Res 5: 171-180
37. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 366: 2443-2454
38. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA (2001) Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2: 1174-1182
39. Uehara S, Grinberg A, Farber JM, Love PE (2002) A role for CCR9 in T lymphocyte development and migration. J Immunol 168: 2811-2819
40. Wang M, Windgassen D, Papoutsakis ET (2008) A global transcriptional view of apoptosis in human T-cell activation. BMC Med Genomics 1: 53
41. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872
42. Wen X, Liu H, Xiao G, Liu X (2011) Downregulation of the transcription factor KLF4 is required for the lineage commitment of T cells. Cell Res 21: 1701-1710
43. Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, Schendel DJ (2012) Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol 189: 598-605
44. Witzens-Harig M, Hose D, Junger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Reme T et al (2013) Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood 121: 4493-4503
45. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72: 917-927
46. Wurbel MA, Malissen M, Guy-Grand D, Meffre E, Nussenzweig MC, Richelme M, Carrier A, Malissen B (2001) Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor gammadelta(+) gut intraepithelial lymphocytes. Blood 98: 2626-2632
47. Yan X, Johnson BD, Orentas RJ (2008) Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. J Immunol 181: 4621-4631
48. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809
49. Zhu Y, Yao S, Chen L (2011) Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34: 466-478
50. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727